Answer
Osimertinib mesylate (Tagrisso) is a tyrosine kinase inhibitor that irreversibly inhibits epidermal growth factor receptors (EGFRs) harbouring sensitising mutations and the TKI-resistance mutation T790M.
Sources for this answer
- Tagrisso 40 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 33Document updated
Sources checked